Jack R. Andrews

Jack R. Andrews, M.D., is an Assistant Professor of Urology at Mayo Clinic, specializing in urologic oncology. He completed his residency in Urology at Mayo Clinic and a Urologic Oncology fellowship at MD Anderson Cancer Center.

• Primary Appointment: Senior Associate Consultant, Department of Urology
• Education: MD (University of Oklahoma), BS (University of Arizona) in Molecular and Cellular Biology with Chemical Engineering minor

Dr. Andrews focuses on prostate cancer research and treatment, particularly clinical trials involving Lutetium PSMA theranostics and PSMA PET/CT imaging. His work includes metastasis-directed therapies, biomarker development, and expanding active surveillance protocols. He leads the Nautilus Trial, the first pre-surgical Lutetium PSMA randomized trial, and serves as Mayo Clinic's site investigator for the Phase 3 BEYER ARASTEP trial.

Recent publications highlight his contributions to PSMA-based biomarkers, oligorecurrent prostate cancer management, and radiopharmaceutical toxicity mitigation. His research bridges surgical innovation with precision medicine approaches.

• Scientific Awards: Gosselin Scholar Grant (2023), Prostate Cancer Foundation Thought Leader of the Future (2023), Vogelzang Scholar (2023)
• Grants: Multiple clinical trial grants from Mayo Clinic, SWOG, and the American Urological Association

As a practicing urologic oncologist, he specializes in nerve-sparing robotic radical prostatectomy, metastasis-directed therapy, and PSMA PET-directed care. His clinical work emphasizes personalized treatment strategies and improving biochemical recurrence monitoring post-surgery.